Artivion, Inc. $AORT Shares Bought by Fred Alger Management LLC

Posted by George Bondi on Jun 17th, 2026

Fred Alger Management LLC increased its position in shares of Artivion, Inc. (NYSE:AORT – Free Report) by 4.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,372,572 shares of the company’s stock after acquiring an additional 55,322 shares during the quarter. Fred Alger Management LLC’s holdings in Artivion were worth $62,603,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AORT. Royal Bank of Canada raised its stake in Artivion by 107.0% during the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock worth $952,000 after acquiring an additional 20,010 shares in the last quarter. AQR Capital Management LLC lifted its position in Artivion by 8.8% during the 1st quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock worth $862,000 after acquiring an additional 2,823 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Artivion by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after buying an additional 1,032 shares during the last quarter. Creative Planning increased its stake in shares of Artivion by 5.6% during the second quarter. Creative Planning now owns 14,272 shares of the company’s stock worth $444,000 after acquiring an additional 753 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after buying an additional 139,370 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Insider Transactions at Artivion

In related news, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the sale, the senior vice president owned 60,259 shares of the company’s stock, valued at $1,247,361.30. The trade was a 42.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

AORT has been the subject of a number of research analyst reports. Stifel Nicolaus set a $45.00 price target on shares of Artivion in a report on Monday, June 1st. Weiss Ratings lowered Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, June 8th. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Canaccord Genuity Group restated a “buy” rating and set a $36.00 price objective on shares of Artivion in a report on Tuesday. Finally, LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target for the company in a report on Friday, April 10th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.17.

Check Out Our Latest Stock Analysis on AORT

Artivion Stock Performance

Shares of AORT stock opened at $21.41 on Wednesday. Artivion, Inc. has a 52 week low of $19.16 and a 52 week high of $48.25. The company has a market cap of $1.04 billion, a PE ratio of 89.23 and a beta of 1.26. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. The company’s fifty day simple moving average is $28.41 and its 200-day simple moving average is $36.62.

About Artivion

(Free Report)

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.